In an ovarian cancer cell line without CCNE1-amplification, Ovsaho cells, a synergy of BI6727- and paclitaxel-treatment was not observed which might suggest that the preservation of endogenous FBW7 levels leading to downregulation of endogenous Cyclin E is an attractive strategy to sensitize ovarian cancer cells with CCNE1-amplification. This evidence concerns the gene CCNE1 and ovarian carcinoma.